Questions Answered in This Report:

    • What are the treatment drivers and goals for moderate to severe CD? 
    • What attributes are key influences, which have limited impact, and which are hidden opportunities? 
    • How do current therapies perform on key treatment drivers and goals for moderate to severe CD? 
    • What are the prevailing areas of unmet need and opportunity in moderate to severe CD? 
    • What trade-offs across different clinical attributes and price are acceptable to and European gastroenterologists for a hypothetical new moderate to severe CD drug? 


The treatment of moderate to severe Crohn’s disease ( CD ) presents an attractive commercial opportunity for new, effective therapies. Despite the revolution that TNF -α inhibitors (, Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) brought to the market, safety risks and efficacy limitations associated with these therapies still exist. In the past two years, the CD market has welcomed two new agents─Takeda’s Entyvio (approved in 2014) and Janssen’s Stelara (approved in 2016)─that offer different mechanisms of action ( MOA s) from the TNF -α inhibitors. The launch of these novel agents has helped address some unmet need, but significant needs persist, especially for patients refractory to available therapies. 
Questions Answered: 
Markets covered: United States, France, Germany, United Kingdom. 
Primary research: Survey of 62 and 30 European gastroenterologists fielded in May 2017. 
Key companies: AbbVie, Biogen, Celltrion, Eisai, Johnson & Johnson, Pfizer, Merck & Co, Takeda, UCB. 
Key drugs: Azathioprine, Cimzia, cx-601, Entyvio, etrolizumab, filgotinib, Inflectra/Remsima/Flixabi, Humira, mongersen, Remicade, Stelara. 

Related Reports

Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. T...

View Details

Crohn's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult

View Details

Crohn's Disease - Unmet Need - Detailed, Expanded Analysis (US & EU)

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s...

View Details